NCAM1 and chronic myelogenous leukemia, BCR-ABL1 positive: NKT cells, defined as CD56-expressing CD3+ T cells, were significantly decreased in CML patients given TKIs plus IFN-α [8.8/μL (95% CI 4.0–19.4)] relative to controls [60.6/μL (95% CI 36.9–99.6), p = 0.001].